| Species |
Human |
| Protein Construction |
TNFRI (Asp41-Asn202)
Accession # P19438-1 |
|
| Purity |
> 95% as analyzed by SDS-PAGE |
| Endotoxin Level |
< 0.2 EU/μg of protein by gel clotting method |
| Biological Activity |
ED50 < 50.0 ng/ml, measured in a cell proliferation assay using 929 cells in the presence of 1.0 ng/ml human TNF-α. |
| Expression System |
CHO |
| Apparent Molecular Weight |
28~35 kDa, on SDS-PAGE under reducing conditions. |
| Formulation |
Lyophilized after extensive dialysis against PBS. |
| Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH₂O or PBS up to 100 μg/ml. |
| Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles. |
| Target Background |
TNF Receptor Type I, is also known as TNF R-p55/p60 and TNFRSF1A. It is a type I transmembrane protein member of the TNF receptor superfamily. It is expressed in most cell types. Binding of either TNF-α or TNF-β to TNF-R1 initiates a signal transduction pathway that results in the activation of the transcription factor NF-κB, whose target genes are involved in the regulation of inflammatory responses, and, in certain cells, induce apoptosis. TNF-R1 is essential for proper development of lymph node germinal centers and Peyer’s patches and for combating intracellular pathogens such as Listeria. It is stored in the Golgi and translocates to the cell surface following proinflammatory stimuli. |
| Synonyms |
Soluble Tumor Necrosis Factor type I; TNFRSF1A; TNFAR; TNF-R55; TNFR60; p55; CD120a |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.
